IONIS HTTRx - Ionis Pharmaceuticals

Drug Profile

IONIS HTTRx - Ionis Pharmaceuticals

Alternative Names: HTT ASO; IONIS-HTTRx; ISIS-443139; ISIS-HTT Rx; RG 6042

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals; Roche
  • Developer Ionis Pharmaceuticals; Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action HD protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease

Most Recent Events

  • 03 Aug 2018 IONIS HTTRx - Ionis Pharmaceuticals receives Priority Medicine (PRIME) status for Huntington's disease in European Union
  • 03 Aug 2018 Roche plans a pivotal phase III trial for Huntington’s disease
  • 11 May 2018 3321314- minor update in AE
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top